CClinicalTrials.gg
CompletedNCT06958718Updated Nov 17, 2025

Ultrasound vs. Surgical ESP Block With Bupivacaine-Dexmedetomidine in Lumbar Fusion Surgery

A Phase 4 interventional study of Ultrasound Guided erector spinae plane block (UB) and Surgical erector spinae plane block (SB) in Post Operative Pain, sponsored by Fayoum University Hospital. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Fayoum University Hospital · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Lumbar spine surgery causes intense post-op pain, peaking within 12 hours and improving by day three. Traditional spinal procedures involve extensive tissue dissection, leading to severe pain and potential complications like delayed mobilization, respiratory issues, and chronic pain. Effective pain management is crucial. Opioid-based relief is standard but comes with side effects (nausea, respiratory depression), increasing hospital stays and costs.

Dexmedetomidine (DEX) is an alpha-2 adrenergic receptor agonist that enhances nerve block duration when combined with local anesthetics (LAs). It works by inhibiting sodium and potassium channels, leading to prolonged hyperpolarization.

Regional nerve blocks, such as thoracic epidurals and fascial plane blocks, improve postoperative pain management and help reduce opioid use, minimizing complications. Various techniques, including ESP blocks, paravertebral Block (PVB), and Serratus anterior Block (SAB) have been explored for acute pain relief.

The Erector Spinae Plane Block (ESPB), initially used for thoracic neuropathic pain, has expanded to thoracic, breast, and abdominal surgeries.

The ESP block is done by injecting a local anesthetic between the transverse process and the erector spinae muscle. Ultrasound guidance helps visualize the spread of the anesthetic and the surrounding anatomy. Previous studies indicate that the ESP block can effectively relieve pain after lumbar spine surgery and may reduce postoperative opioid use when local anesthetics are applied to the wound and deep tissues. Based on this, performing the ESP block directly by the surgical team, using a local anesthetic between the erector spinae muscle and transverse process with direct view and free hand, may yield similar results to the ultrasound guided technique. The current study aims to evaluate the analgesic efficacy of Ultrasound-Guided Erector Spinae Plane Block in comparison with surgical Erector Spinae Plane Block using a mixture of bupivacaine and dexmedetomidine in lumbar Spinal fusion Surgeries.

Read the detailed description

After approval of the local institutional ethics committee and local institutional review board. Patients scheduled for elective lumbar spinal Fusion surgeries and fulfilling the inclusion criteria in Fayoum University Hospital starting from February 2025 will be enrolled in this prospective randomized study until fulfilling the sample size. The eligible participants will sign a detailed informed consent before recruitment.

Randomization will be done using computer-generated random numbers placed in separate opaque envelopes and opened by the anesthesiologist just before induction of anesthesia, eligible patients will be randomized with 1:1 allocation ratio into two groups:

  • The surgical ESPB group (SB)
  • The Ultrasound guided ESPB group (UB) Both the anesthesiologist and the surgeons performing the US guided ESP block and surgical ESP block will not be further involved in the study. Another anesthesiologist will be responsible for further patient care and data collection. This anesthesiologist and the patient will be blinded from the group assignments.

General anesthesia:

Upon arrival at the operating theatre, all patients will be monitored using electrocardiography, pulse-oximetry, capnography, and Noninvasive blood pressure (NIBP). After routine history, examination, and review of laboratory results, General anesthesia will be induced with intravenous propofol (2 mg/kg), fentanyl (1 μg/kg), and atracurium (0.5mg/kg). After that, patients will be intubated and placed in a prone position. Anesthesia will be maintained using IV atracurium and inhalational anesthesia (isoflurane) in an oxygen and fresh air mixture. All patients will receive intravenous Ketorolac (30 mg), Nalbuphine (10 mg), and Ondansetron 8 mg approximately 30 min before the end of the surgery.

Block technique:

For patients in Group UB, an ultrasound-guided ESP block will be performed after the surgical incision is closed and before extubation, while the patient remains in the prone position. A linear high-frequency transducer (L6-12 linear array transducer (6-12 MHz) on GE Healthcare logiq p7, made in Korea) will be positioned in a sagittal orientation, 4 cm lateral to the L3 transverse process. A 22 G × 88 mm block needle will be inserted in the craniocaudal direction, with the needle tip placed beneath the erector spinae muscle and above the hyperechoic transverse process. The needle tip position will be confirmed via saline injection. Once correct needle placement is verified, 40 mL of 0.25% bupivacaine, combined with 0.5 μg/kg dexmedetomidine 15 will be administered divided on both sides. For patients in group SB, the injectate will be prepared with the help of the anesthetist by adding 0.5 μg/kg dexmedetomidine to 40 mL of 0.25% bupivacaine. This volume will be divided into 8 injections, four 5 ml injections on each side. The surgeons will perform the block just before starting the wound closure stage. The surgical ESP block technique consists of injections at four bilateral levels, starting from one level above the operated vertebra and covering all surgical segments using a 22G × 88 mm needle. The needle will be inserted to contact the transverse process, and the injectate will be delivered between the erector spinae muscle and the transverse process at each level.

Postoperative pain management:

After discharge to ward, all patients will receive paracetamol 1g / 8hrs, ketorolac 30 mg/ 12hrs and nalbuphine 5mg as a rescue analgesia. The patient's pain will be evaluated using a Visual Analog Scale (VAS) where 0 denotes no pain, and 10 represents the most intense pain ever experienced. Dynamic and static VAS scores will be recorded in the postoperative period at 1, 4, 8, 16, 24, 36 and 48 hours. Patients with VAS scores of 4 or higher will receive Nalbuphine (5 mg) for rescue analgesia.

sample size calculation and statistical analysis : Sample size was calculated using IBM SPSS 29 software for windows (IBM Co., Armonk, NY, USA). Calculation of the sample size was based on the ability to detect a difference of one point in the VAS score between the two groups based on the results of a study by Kaciroglu, A. et al. At least 23 patients are needed per group to detect this difference at α level of 0.05 and study power of 80%. We decided to recruit 26 patients per group to compensate for any possible withdrawals up to 10% and to increase the study power. The sample size calculation was based on the independent samples t test. Statistical analysis will be performed using SPSS for Windows, version 29 (IBM Corp., and Armonk, New York, USA). Descriptive statistics will be presented in the form of (mean ± SD), or (median with interquartile range) for numerical data, while numbers and percentages will be used for categorical data. Testing for normality of distribution will be done using the Shapiro-Wilk test. Categorical variables will be analyzed using Chi-square test or Fisher's exact test. Differences in parametric normally distributed numerical data will be compared using Student's t tests, While the non-parametric data will be compared using Mann Whitney U-test. Results will be considered statistically significant if the p value is less than 0.05.

02

Conditions studied

  • Post Operative Pain

Keywords

  • lumbar spinal surgery
  • Pain
  • ESPB
  • Ultrasound guided ESPB
  • Surgical ESPB
  • Dexmedetomidine
03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's enrollment of 52 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Fayoum University Hospital is the lead sponsor of 73 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

- American Society of Anesthesiologists (ASA) I-Ⅲ patients scheduled for elective two or three levels of lumbar spinal fusion surgeries by the same surgical team.

Exclusion criteria

Exclusion Criteria:

  • Patient refusal.
  • Body mass index > 30 kg/m2
  • Significant renal, hepatic, or cardiovascular diseases.
  • History of allergy to one of the study drugs (local anesthetics, opioids, or dexmedetomidine).
  • Any contraindications to regional anesthesia like local infection or abnormal coagulation function.
  • Pregnant or breastfeeding women.
  • Chronic opioid use, history of chronic pain, or cognitive disorders.
  • Emergent surgeries.
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Active comparator
    Ultrasound Guided erector spinae plane block (UB)

    the block will be done using ultrasound device after wound closure

    Procedure: Ultrasound Guided erector spinae plane block (UB) · Drug: Dexmedetomidine · Drug: Bupivacaine Hcl 0.5% Inj

  • Active comparator
    Surgical erector spinae plane block (SB)

    the block will be done surgically before wound closure

    Procedure: Surgical erector spinae plane block (SB) · Drug: Dexmedetomidine · Drug: Bupivacaine Hcl 0.5% Inj

Interventions

  • ProcedureUltrasound Guided erector spinae plane block (UB)

    Ultrasound Guided erector spinae plane block (UB) with 40 ml Bupivacaine HCL mixed with 0.5 μg/kg dexmedetomidine .. After the surgical incision is closed and before extubation, while the patient remains in the prone position. A linear high-frequency transducer (L6-12 linear array transducer (6-12 MHz) on GE Healthcare logiq p7, made in Korea) will be positioned in a sagittal orientation, 4 cm lateral to the L3 transverse process. A 22 G × 88 mm block needle will be inserted in the craniocaudal direction, with the needle tip placed beneath the erector spinae muscle and above the hyperechoic transverse process. The needle tip position will be confirmed via saline injection. Once correct needle placement is verified, 40 mL of 0.25% bupivacaine, combined with 0.5 μg/kg dexmedetomidine 15 will be administered divided on both sides.

  • ProcedureSurgical erector spinae plane block (SB)

    Surgical erector spinae plane block (SB) with 40 ml Bupivacaine HCL mixed with 0.5 μg/kg dexmedetomidine ..This volume will be divided into 8 injections, four 5 ml injections on each side. The surgeons will perform the block just before starting the wound closure stage. The surgical ESP block technique consists of injections at four bilateral levels, starting from one level above the operated vertebra and covering all surgical segments using a 22G × 88 mm needle. The needle will be inserted to contact the transverse process, and the injectate will be delivered between the erector spinae muscle and the transverse process at each level.

  • DrugDexmedetomidine

    0.5 μg/kg dexmedetomidine added to block solution

    Also known as: precedex

  • DrugBupivacaine Hcl 0.5% Inj

    40 ml Bupivacaine HCL

    Also known as: Marcaine

06

What researchers measure

Primary outcomes

  1. QAQStatic VAS score one hour postoperatively.

    Visual Analog Scale (VAS) tool used to measure pain of patients after surgery, consist of 100mm length scale where 0 = "no pain" and 100 = "worst imaginable pain". static VAS score to be obtained one hour after surgery.

    Time frame: one hour after surgery

Secondary outcomes

  1. Postoperative static VAS scores.

    Visual Analog Scale (VAS) tool used to measure pain of patients after surgery, consist of 100mm length scale where 0 = "no pain" and 100 = "worst imaginable pain". static VAS score to be obtained at 2, 4, 8, 16, 24, 36, and 48 hours after the block.

    Time frame: At 48 hours after the block

  2. Postoperative dynamic VAS scores.

    Visual Analog Scale (VAS) tool used to measure pain of patients after surgery, consist of 100mm length scale where 0 = "no pain" and 100 = "worst imaginable pain". Dynamic VAS score to be obtained at 2, 4, 8, 16, 24, 36, and 48 hours after the block.

    Time frame: At 48 hours after the block

  3. Time consumed in the block.

    Time of the block procedure

    Time frame: the time After starting blocking procedure till finishing procedure up to 1 hour

  4. The time of the first postoperative analgesic request.

    The time consumed after block until first request of analgesia.

    Time frame: the time After blocking procedure till the first request of analgesia up to 48 hours

  5. Total postoperative needs of nalbuphine.

    amount of nalbuphine used in milligrams.

    Time frame: At first 24 hours after ESP block.

  6. Heart rate (HR)

    at 0 (block time), 5min, 10 min, 15 min, 30 min, 1h, 2h, 4h, 8h, 16h, 24h, 36h, and 48h after ESP block.

    Time frame: Assessed up to 48 hours after block.

  7. Mean Arterial Pressure (MAP)

    at 0 (block time), 5min, 10 min, 15 min, 30 min, 1h, 2h, 4h, 8h, 16h, 24h, 36h, and 48h after ESP block.

    Time frame: Assessed up to 48 hours after block.

  8. number of participants with nausea and vomiting.

    Complications related to the block or study medications.

    Time frame: Assessed up to 48 hours after block.

  9. Incidence of respiratory depression

    Respiratory Rate \< 8 bpm.

    Time frame: At first 24 hours after ESP block.

  10. number of participants with pruritus

    Complications related to the block or study medications

    Time frame: At first 24 hours after ESP block.

  11. number of participants with manifestations of systemic toxicity from local anesthetic drugs

    Assess for neurological or cardiovascular toxicity symptoms

    Time frame: At first 24 hours after ESP block.

  12. Sedation level

    Assess sedation level, using a four-point sedation scale (score 1 = spontaneous eye opening \[awake and alert\]; score 2 = drowsy, responsive to verbal stimuli. score 3 = drowsy, arousable to physical stimuli; score 4 = unresponsive) ِِAssessed at 1, 2, 4, 8, 16, 24 hours after the block

    Time frame: Assessed up to 24 hours after block.

  13. 24h Quality of recovery questionnaire (QoR-15)

    15 items questionnaire used to evaluate the quality of recovery 24h after surgery, an aggregate score from 0 (no recovery) to 150 (total recovery)

    Time frame: 24 hours after surgery.

  14. Length of hospital stay

    measured in days, from day 0, the day of surgery, until discharge

    Time frame: The Time of stay (surgery day) until hospital discharge up to 7 days

07

Study locations

1 site
  • Fayoum University hospital
    Al Fayyum, Fayoum Governorate 63514, Egypt
08

References and documents

Publications

  • Kleif J, Gogenur I. Severity classification of the quality of recovery-15 score-An observational study. J Surg Res. 2018 May;225:101-107. doi: 10.1016/j.jss.2017.12.040. Epub 2018 Feb 21. PubMed 29605019 ↗
  • Kraiwattanapong C, Arnuntasupakul V, Kantawan R, Woratanarat P, Keorochana G, Langsanam N. Effect of Multimodal Drugs Infiltration on Postoperative Pain in Split Laminectomy of Lumbar Spine: A Randomized Controlled Trial. Spine (Phila Pa 1976). 2020 Dec 15;45(24):1687-1695. doi: 10.1097/BRS.0000000000003679. PubMed 32890299 ↗
  • Singh S, Choudhary NK, Lalin D, Verma VK. Bilateral Ultrasound-guided Erector Spinae Plane Block for Postoperative Analgesia in Lumbar Spine Surgery: A Randomized Control Trial. J Neurosurg Anesthesiol. 2020 Oct;32(4):330-334. doi: 10.1097/ANA.0000000000000603. PubMed 31033625 ↗
  • Devin CJ, McGirt MJ. Best evidence in multimodal pain management in spine surgery and means of assessing postoperative pain and functional outcomes. J Clin Neurosci. 2015 Jun;22(6):930-8. doi: 10.1016/j.jocn.2015.01.003. Epub 2015 Mar 9. PubMed 25766366 ↗
  • Qiu Y, Zhang TJ, Hua Z. Erector Spinae Plane Block for Lumbar Spinal Surgery: A Systematic Review. J Pain Res. 2020 Jul 1;13:1611-1619. doi: 10.2147/JPR.S256205. eCollection 2020. PubMed 32669870 ↗
  • Liang X, Zhou W, Fan Y. Erector spinae plane block for spinal surgery: a systematic review and meta-analysis. Korean J Pain. 2021 Oct 1;34(4):487-500. doi: 10.3344/kjp.2021.34.4.487. PubMed 34593667 ↗
  • Chitnis SS, Tang R, Mariano ER. The role of regional analgesia in personalized postoperative pain management. Korean J Anesthesiol. 2020 Oct;73(5):363-371. doi: 10.4097/kja.20323. Epub 2020 Aug 5. PubMed 32752602 ↗
  • Bajwa S, Kulshrestha A. Dexmedetomidine: an adjuvant making large inroads into clinical practice. Ann Med Health Sci Res. 2013 Oct;3(4):475-83. doi: 10.4103/2141-9248.122044. PubMed 24379995 ↗
  • Prabhakar NK, Chadwick AL, Nwaneshiudu C, Aggarwal A, Salmasi V, Lii TR, Hah JM. Management of Postoperative Pain in Patients Following Spine Surgery: A Narrative Review. Int J Gen Med. 2022 May 2;15:4535-4549. doi: 10.2147/IJGM.S292698. eCollection 2022. PubMed 35528286 ↗
  • Bianconi M, Ferraro L, Ricci R, Zanoli G, Antonelli T, Giulia B, Guberti A, Massari L. The pharmacokinetics and efficacy of ropivacaine continuous wound instillation after spine fusion surgery. Anesth Analg. 2004 Jan;98(1):166-172. doi: 10.1213/01.ANE.0000093310.47375.44. PubMed 14693613 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06958718
Lead sponsor
Fayoum University Hospital
Responsible party
Mohamed Ahmed Hamed (Associate Professor of Anesthesiology, Fayoum University Hospital) — Principal investigator
First posted
May 6, 2025
Start date
May 6, 2025
Primary completion
Aug 31, 2025
Completion
Aug 31, 2025
Last update
Nov 17, 2025

Study contacts

Mohamed A Hamed, MD
principal investigator · Fayoum University Hospital
Mohamed A Elsaeed, MD
study director · Fayoum University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion